Recommended as Stock of the Week on January 31, 2026
Regeneron: Dupixent expansion meets Eylea patent cliff - Biotech quality test
Scores at time of recommendation (January 31, 2026)
Leeway Score
64/100
Excellent
Business Rating
44/100
Fair
Market-Fit Rating
65/100
Fair
Cycle Rating
83/100
Excellent
5-year stock timeline
Regeneron's last five years have been defined by the transition from a COVID beneficiary back to a Dupixent/Eylea-led immunology and ophthalmology powerhouse, with sentiment moving from "COVID trade" to "defensive growth compounder" and then "high‑quality but fully priced growth."[12]
2019–Early 2020: Pre‑COVID growth story
- In 2019, the narrative centered on Dupixent's rapid uptake in atopic dermatitis and asthma and Eylea's dominance in retinal disease, positioning Regeneron as a durable growth biotech rather than a one‑product story.[12]
- Investor perception was "high‑quality growth pharma," driven by visible Dupixent indication expansion (new asthma and pediatric approvals globally) and steady Eylea franchise cash flows.[12]
- Technically, REGN had recovered from mid‑2010s stagnation and was consolidating in a large multi‑year range; by late 2019/early 2020 it was turning higher as Dupixent forecasts were raised, positioning for an upside breakout when COVID news arrived.[10]
2020: COVID antibody & explosive rerating
- In 2020, REGN became a COVID play as REGEN‑COV (casirivimab/imdevimab) advanced rapidly and received Emergency Use Authorization, adding a substantial, high‑margin but clearly temporary revenue stream.[12][9]
- The narrative layered "pandemic winner" onto the existing Dupixent/Eylea growth story; bulls framed it as a cash‑rich innovator with optionality, while skeptics warned about peak COVID revenues and eventual normalization.[12][3]
- The stock staged a major uptrend and rerating, breaking out of its prior multi‑year range with very strong gains through mid‑2020 before momentum flattened as the market started pricing in the finite life of COVID antibody sales.[10]
2021–2022: COVID fade, Dupixent/Eylea reconfirm leadership
- By early 2022, the FDA sharply limited REGEN‑COV's use due to lack of efficacy against Omicron, effectively eliminating COVID antibody revenues. Yet Regeneron still reported strong Q1 results as Dupixent and Eylea drove revenue growth with double‑digit gains.[12]
- Management and investors pivoted the narrative back to "core franchise resilience," emphasizing Dupixent's expanding indications—asthma in children, eosinophilic esophagitis—and Eylea's continued leadership in diabetic and retinal disease, while smaller oncology assets and the Checkmate Pharmaceuticals acquisition reinforced the longer‑term pipeline story.[12]
- On the chart, REGN entered a choppy consolidation phase: COVID-trade froth bled off, but downside was limited as fundamentals re‑anchored on durable Dupixent/Eylea cash flows. The stock traded in a broad sideways range with several failed breakouts as investors evaluated life after COVID.[10]
2023–Mid 2024: High‑dose Eylea, Dupixent expansion and quality‑growth phase
- Focus shifted to extending the Eylea franchise through high‑dose formulations and dosing extensions, and continuing Dupixent's growth across multiple Type 2 inflammatory indications. Quarterly reports highlighted strong Dupixent growth and Eylea's resilience despite emerging competition.[12][3]
- The narrative evolved into a "defensive compounder / high‑quality growth" story: investors saw a large, visible Dupixent runway, robust margins, and a deep pipeline, but also questioned valuation as the stock embedded optimistic long‑term expectations.[9][12]
- Technically, REGN worked higher in a broad, multi‑month uptrend, making new highs and approaching the upper end of its long‑term range. Periodic pullbacks around data and regulatory headlines on Eylea and Dupixent mostly resolved as buy‑the‑dip opportunities.[10]
Late 2024–Early 2025: Capital return, pipeline balancing and rich‑valuation debate
- In early 2025, Regeneron reported full‑year 2024 results, beat consensus overall despite softer‑than‑hoped high‑dose Eylea and Dupixent sales, and announced its first recurring quarterly dividend of $0.88 along with an increased share‑repurchase authorization of approximately $4.5 billion.[2][14]
- These moves reinforced the perception of Regeneron as a mature, cash‑generative biopharma transitioning further into a "compounder with capital return," while investors weighed modest near‑term growth volatility in key franchises against long‑term pipeline optionality.[2][14]
- Around this period, the stock traded near its 5‑year highs, reflecting a strong multi‑year uptrend from the COVID low and later consolidations. Price action showed sharp reactions around data and guidance updates but remained broadly in a high‑level range consistent with a "quality but fully‑valued" narrative.[10][2]
Key Points
- Q4 2025: Sales +3% to 3.9 billion USD, adjusted EPS USD 11.44 (consensus USD 10.56) - Dupixent grows 32% to 17.8 bn. USD Annual turnover
- Eylea HD +66% to 506 million USD, while Legacy-Eylea slumps -52% due to biosimilar competition and compounding pressure
- Libtayo 425 million USD (+13% YoY), market leader in advanced forms of skin cancer with expansion into cervical cancer
- Net profit 1.2 billion USD, free cash flow 4.1 billion USD (2025), net liquidity 16.2 bn. USD - 3.4 billion USD Share buybacks
Investment Thesis
Regeneron's Q4 beat shows operational stability driven by Dupixent growth, while Eylea HD only partially compensates for legacy erosion. The pipeline will deliver at least four FDA approvals by the end of 2026, including three new active ingredients, but the patent cliff from 2031 at Dupixent casts a shadow ahead - Sanofi has already admitted that it will not be able to close the sales gap. With a P/E ratio of 17.5, a 31% net margin and solid balance sheet quality (equity ratio 78%), the share is trading below analysts' consensus of USD 832. The valuation reflects both the essential nature of the core products (blindness prevention, severe dermatitis) and structural risks due to Medicare price negotiations and product concentration. For patient investors, the combination of FDA catalysts, institutional buying and quality management offers an interesting entry point - provided the regulatory uncertainties of the Trump era are priced in.
Key risks and downside factors
Regeneron Pharmaceuticals operates across ophthalmology, immunology, oncology, and cardiovascular disease—territories where it contends with formidable competitors like Amgen, Novartis, Roche, and Sanofi. The company's risk profile centers on a concentrated portfolio: Eylea and Dupixent carry outsized weight, while biosimilar erosion and innovative challengers loom. Beyond that sit the usual biotech pressures—R&D uncertainty, regulatory hurdles, and the shifting ground of reimbursement policy. There's also the matter of dependencies: key collaborations and manufacturing partners that, if disrupted, could create real friction. To hold its position, Regeneron needs sustained innovation and sharp IP defense. Without both, margin compression and market share loss become more than theoretical concerns.
- Heavy reliance on a handful of blockbusters—Eylea and Dupixent chief among them—creates real vulnerability. Exclusivity cliffs and biosimilar competition could carve meaningful holes in the revenue picture.
- Intense competition across ophthalmology, immunology, oncology, and cardiovascular markets—from established global biopharma giants and nimble biotechs alike—creates persistent pressure on pricing, margins, and market share.[1][7][15]
- R&D, regulatory, and clinical trial risks—potential delays, failures, safety issues, or the inability to secure and maintain approvals and intellectual property protection for pipeline candidates.
- The company faces operational and policy risks stemming from its dependence on collaborators, contract manufacturers, and third-party payors. Additionally, shifts in drug pricing, reimbursement policies, and healthcare regulations across key markets pose material headwinds.
Competitive landscape
Regeneron Pharmaceuticals stands as a substantial U.S. biotech player built around innovative biologic therapies—Eylea and Dupixent chief among them—competing directly against global pharmaceutical heavyweights across immunology, ophthalmology, and oncology. The company operates in markets where competitors possess deep pipelines and formidable commercial reach, while navigating intensifying biosimilar competition. That pressure sharpened considerably in 2024 when Eylea lost U.S. regulatory exclusivity. The risk picture here is fairly straightforward: heavy reliance on a concentrated product portfolio, relentless R&D and pricing demands, and a regulatory and healthcare landscape that keeps shifting beneath your feet in the markets that matter most.
| Company | Ticker |
|---|---|
| Amgen Inc. | AMGN.NASDAQ |
| Gilead Sciences, Inc. | GILD.NASDAQ |
| Moderna, Inc. | MRNA.NASDAQ |
| Vertex Pharmaceuticals Incorporated | VRTX.NASDAQ |
| AbbVie Inc. | ABBV.NYSE |
| Eli Lilly and Company | LLY.NYSE |
| Merck & Co., Inc. | MRK.NYSE |
| Pfizer Inc. | PFE.NYSE |
Private competitors
- Early-stage biotech platforms in immunology and oncology—private firms operating at Regeneron scale, many with overlapping pipelines
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialCatalysts
- FDA decision on new Eylea HD filler manufacturer in Q2 2026 after Catalent delays
- Dupixent COPD approval (November 2025) and Libtayo cervical cancer expansion each unlock 2+ billion USD peak sales potential
- At least three new molecular entities with FDA approvals in the next 12 months
- GLP-1 agonist data H1 2026 as diversification in obesity market
- Possible agreement with Trump administration on drug prices along the lines of other pharmaceutical companies
Analysis
Regeneron predominantly addresses highly urgent medical needs in serious diseases where the absence of therapy means irreversible damage or significant loss of quality of life - Eylea prevents blindness in wet macular degeneration, Dupixent alleviates severe atopic dermatitis with limited alternatives, Libtayo treats advanced forms of skin cancer. The core portfolio remains essential with minimal lifestyle exposure, which ensures structural pricing power and demand stability. The management team around founder Leonard Schleifer and Chief Scientific Officer George Yancopoulos has built up several internally developed blockbusters over decades, made focused R&E investments and established the strategically valuable Sanofi partnership - remaining risks lie in succession planning and recent production delays at Catalent. Like all pharmaceutical companies, Regeneron is exposed to significant regulatory risks, particularly from Medicare price negotiations and political pressure on drug prices, while its dependence on a few blockbusters creates vulnerability. However, the broad pipeline of new approvals and strategic partnerships offer diversification, and the latest quarterly results show solid operational strength with an expected recovery from 2026. The regulatory landscape remains challenging, but the combination of innovation, essential therapies and sound management provides buffers against political interference - albeit without guarantees in current US healthcare policy.
Performance Figures of Regeneron Pharmaceuticals Inc
1M High / Low
815.00 / 718.38
52W High / Low
821.11 / 476.49
5Y High / Low
1211.20 / 441.00
1M
+8.25%
3M
+13.06%
6M
+32.83%
1Y
+18.46%
3Y
+6.57%
5Y
+67.27%
Relative Performance vs Benchmarks
| Period | Regeneron Pharmaceuticals Inc | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +8.25% | +9.43% | +9.52% |
| 3M | +13.06% | +5.14% | +9.70% |
| 6M | +32.83% | +29.93% | +24.77% |
| 1Y | +18.46% | +8.81% | +5.15% |
| 3Y | +6.57% | -54.90% | -67.86% |
| 5Y | +67.27% | -12.74% | -19.95% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 18.9 | 5.9 | 2.7 | 17.1 |
| 1Y ago | 17.4 | 5.4 | 2.2 | 17.3 |
| 3Y ago | 19.7 | 7.0 | 3.8 | 17.0 |
| 5Y ago | 15.4 | 6.4 | 4.9 | 20.6 |
Frequently Asked Questions
Is Regeneron a good investment?
Regeneron has a Leeway Score of 64.1/100, which is rated as Excellent. The Leeway Score combines business quality, fundamental evaluation, and valuation cycle into a comprehensive assessment. A higher score indicates stronger investment quality based on AI-powered fundamental analysis.
What does Regeneron do?
Regeneron is a company characterized by the following investment thesis: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals Inc operates in the Healthcare / Biotechnology industry is based in USA employs around 15,410 people. Regeneron Pharmaceuticals Inc recently reported revenue of about 14.34B USD, a profit margin of 31.41%, return on equity of 14.86%, a market capitalisation around 84.91B USD, valuation multiples of roughly 19.4x earnings, 5.9x sales, 2.7x book value. Analyst consensus currently expects earnings per share of around 47.01 USD with year‑over‑year growth of 18.98%. Regeneron Pharmaceuticals Inc has an ongoing dividend policy and pays around 3.52 USD per share (0.45% yield).
What are the key metrics for REGN.NASDAQ?
Key metrics for REGN.NASDAQ include valuation (P/E 17.5, P/S 5.6, P/B 2.6), profitability (profit margin 32.13%, ROE 15.19%), and growth (revenue 0.90%, earnings 18.00%). Market capitalization is 79.71B USD. These metrics give an overview of the company's financial performance and valuation.
How has Regeneron's stock price performed?
Regeneron's stock has returned — over 1 year, — over 3 years, and — over 5 years. Performance can vary depending on market conditions and company developments.
How is REGN.NASDAQ valued?
REGN.NASDAQ has the following valuation metrics: P/E Ratio: 17.5, P/S Ratio: 5.6, P/B Ratio: 2.6. These metrics help assess whether the stock is fairly valued compared to its fundamentals.
What are the growth catalysts for Regeneron?
The key growth catalysts for Regeneron are:
- FDA decision on new Eylea HD filler manufacturer in Q2 2026 after Catalent delays
- Dupixent COPD approval (November 2025) and Libtayo cervical cancer expansion each unlock 2+ billion USD peak sales potential
- At least three new molecular entities with FDA approvals in the next 12 months
- GLP-1 agonist data H1 2026 as diversification in obesity market
- Possible agreement with Trump administration on drug prices along the lines of other pharmaceutical companies
What are the key risks when investing in REGN.NASDAQ?
Key risks for REGN.NASDAQ include: Regeneron Pharmaceuticals operates across ophthalmology, immunology, oncology, and cardiovascular disease—territories where it contends with formidable competitors like Amgen, Novartis, Roche, and Sanofi. The company's risk profile centers on a concentrated portfolio: Eylea and Dupixent carry outsized weight, while biosimilar erosion and innovative challengers loom. Beyond that sit the usual biotech pressures—R&D uncertainty, regulatory hurdles, and the shifting ground of reimbursement policy. There's also the matter of dependencies: key collaborations and manufacturing partners that, if disrupted, could create real friction. To hold its position, Regeneron needs sustained innovation and sharp IP defense. Without both, margin compression and market share loss become more than theoretical concerns.
- Heavy reliance on a handful of blockbusters—Eylea and Dupixent chief among them—creates real vulnerability. Exclusivity cliffs and biosimilar competition could carve meaningful holes in the revenue picture.
- Intense competition across ophthalmology, immunology, oncology, and cardiovascular markets—from established global biopharma giants and nimble biotechs alike—creates persistent pressure on pricing, margins, and market share.[web:1][web:7][web:15]
- R&D, regulatory, and clinical trial risks—potential delays, failures, safety issues, or the inability to secure and maintain approvals and intellectual property protection for pipeline candidates.
- The company faces operational and policy risks stemming from its dependence on collaborators, contract manufacturers, and third-party payors. Additionally, shifts in drug pricing, reimbursement policies, and healthcare regulations across key markets pose material headwinds.
Who are the main competitors of Regeneron?
Regeneron competes with several listed peers in its sector. Regeneron Pharmaceuticals stands as a substantial U.S. biotech player built around innovative biologic therapies—Eylea and Dupixent chief among them—competing directly against global pharmaceutical heavyweights across immunology, ophthalmology, and oncology. The company operates in markets where competitors possess deep pipelines and formidable commercial reach, while navigating intensifying biosimilar competition. That pressure sharpened considerably in 2024 when Eylea lost U.S. regulatory exclusivity. The risk picture here is fairly straightforward: heavy reliance on a concentrated product portfolio, relentless R&D and pricing demands, and a regulatory and healthcare landscape that keeps shifting beneath your feet in the markets that matter most.
- Amgen Inc. (AMGN.NASDAQ)
- Gilead Sciences, Inc. (GILD.NASDAQ)
- Moderna, Inc. (MRNA.NASDAQ)
- Vertex Pharmaceuticals Incorporated (VRTX.NASDAQ)
- AbbVie Inc. (ABBV.NYSE)
- Eli Lilly and Company (LLY.NYSE)
- Merck & Co., Inc. (MRK.NYSE)
- Pfizer Inc. (PFE.NYSE)
What is Regeneron's average dividend yield?
Across past payouts, Regeneron's average dividend yield at payment date has been 0.14%.
Key Metrics
Market Capitalization
79.71B USD
P/E Ratio
17.55
Analyst Target Price
832.15 USD
Valuation Metrics
P/S Ratio
5.64
P/B Ratio
2.60
Profitability Metrics
Profit Margin
32.13%
Operating Margin
29.56%
Return on Equity
15.19%
Return on Assets
6.16%
Growth Metrics
Revenue Growth
0.90%
Earnings Growth
18.00%
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.94 USD | — | 0.14% |
| 2025 | 0.88 USD | 0.13% | |
| 2025 | 0.88 USD | 0.15% | |
| 2025 | 0.88 USD | 0.15% | |
| 2025 | 0.88 USD | 0.13% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
79.2%
Beat estimate
19.2%
Miss estimate
+29.15%
Avg surprise when beat
-21.62%
Avg surprise when miss
Analyst estimates for upcoming periods
Next year
December 31, 2027
Consensus47.01
Range38.31 – 59.71
Next quarter
June 30, 2026
Consensus10.67
Range7.36 – 13.43
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 14.34B | 14.20B | 13.12B | 12.17B | 16.07B |
| Operating income (EBIT) | 3.58B | 3.99B | 4.05B | 5.39B | 9.00B |
| Net income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B |
| Free cash flow | 4.08B | 3.66B | 3.67B | 4.42B | 6.53B |
| Total assets | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B |
| Equity | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B |
| Net debt | -412.20M | 216.20M | -27.10M | -404.50M | -185.90M |
© Leeway
PWP Leeway UG (haftungsbeschränkt)
PWP Leeway UG (haftungsbeschränkt)
